Testing DMT to Treat Depression

Psychoactive drug DMT (aka N, N-Dimethyltryptamine) is known for its life-altering, metaphysical trips, but scientists are now looking into its potential to treat depression. Small Pharma, a Canadian drug development company, is working on combining DMT with regular therapy to ease depression in treatment-resistant patients. In September, the company completed phase one of clinical trials—the first company to do so—by testing DMT on volunteers. Now, …

Psychedelic Drug Developers Go Public

When New York-based psychedelic drug developer MindMed went public this week, they sought funding to continue work on mental health treatment that looks to LSD (a Schedule 1 drug) as its active ingredient. They’re the second psychedelics company to go down this financial path in the US, with a third not far behind. This news warrants attention because of the lack of legalization for psychedelics …